Local immunostimulation leading to rejection of accepted male skin grafts by female mice as a model for cancer immunotherapy

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 9, 2014, Pages 3502-3507

  Bourdeaux, Christophe ^a,b   Lurquin, Christophe ^a,c   Jacquemart, Isabelle ^a,c   Lethé, Bernard ^a,c   Brasseur, Francis ^a,c   Van Baren, Nicolas ^a,c   Baurain, Jean François ^b   Dyson, Julian ^d   Van Snick, Jacques ^c   Uyttenhove, Catherine ^a,c   Boon, Thierry ^a,c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c DE DUVE INSTITUTE   (Belgium)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Immunology; Transplantation

Indexed keywords

ALPHA INTERFERON; GARDIQUIMOD; HY ANTIGEN; IMIQUIMOD; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1ALPHA; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL INVASION; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOGENICITY; IMMUNOSTIMULATION; IMMUNOSUPPRESSIVE TREATMENT; LOCAL THERAPY; MALE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEX DIFFERENCE; SKIN GRAFT; T LYMPHOCYTE; TOXICITY;

IMMUNOLOGY; TRANSPLANTATION;

ADOPTIVE TRANSFER; ANIMALS; CYTOKINES; DISEASE MODELS, ANIMAL; DNA PRIMERS; FEMALE; GRAFT REJECTION; IMMUNE TOLERANCE; IMMUNIZATION; MALE; MICE; MICE, INBRED CBA; NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SEX FACTORS; SKIN TRANSPLANTATION;

EID: 84895835424     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1401115111     Document Type: Article

References (34)

1. Boon T, Coulie PG, Van den Eynde BJ, van der Bruggen P (2006) Human T cell responses against melanoma. Annu Rev Immunol 24:175-208.
2. van der Bruggen P, et al. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254(5038):1643-1647.
3. Brichard V, et al. (1993) The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med 178(2):489-495.
4. Marchand M, et al. (1999) Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80(2):219-230.
5. Marchand M, et al. (1995) Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 63(6):883-885.
6. Schuler-Thurner B, et al. (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptideloaded monocyte-derived dendritic cells. J Exp Med 195(10):1279-1288.
7. Germeau C, et al. (2005) High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med 201(2): 241-248.
8. Rosenberg SA, et al. (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med 319(25):1676-1680.
9. Yannelli JR, et al. (1996) Growth of tumor-infiltrating lymphocytes from human solid cancers: Summary of a 5-year experience. Int J Cancer 65(4):413-421.
10. Lurquin C, et al. (2005) Contrasting frequencies of antitumor and anti-vaccine T cells in metastases of a melanoma patient vaccinated with a MAGE tumor antigen. J Exp Med 201(2):249-257.
11. Garrido F, et al. (1993) Natural history of HLA expression during tumour development. Immunol Today 14(10):491-499.
12. Garrido F, et al. (1997) Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18(2):89-95.
13. Massagué J (2008) TGFbeta in cancer. Cell 134(2):215-230.
14. Pilotte L, et al. (2012) Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase. Proc Natl Acad Sci USA 109(7):2497-2502.
15. Uyttenhove C, et al. (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10): 1269-1274.
16. Feng S, et al. (2012) Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. JAMA 307(3):283-293.
17. Sánchez-Fueyo A, Strom TB (2011) Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 140(1):51-64.
18. Kirkwood JM, et al. (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14(1):7-17.
19. Millrain M, et al. (2005) Identification of the immunodominant HY H2-D(k) epitope and evaluation of the role of direct and indirect antigen presentation in HY responses. J Immunol 175(11):7209-7217.
20. Scott DM, et al. (1995) Identification of a mouse male-specific transplantation antigen, H-Y. Nature 376(6542):695-698.
21. Guilloux Y, et al. (1996) A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. J Exp Med 183(3):1173-1183.
22. Robertson NJ, et al. (2007) Natural regulation of immunity to minor histocompatibility antigens. J Immunol 178(6):3558-3565.
23. Chappert P, Schwartz RH (2010) Induction of T cell anergy: Integration of environmental cues and infectious tolerance. Curr Opin Immunol 22(5):552-559.
24. Schwartz RH (2003) T cell anergy. Annu Rev Immunol 21:305-334.
25. Fierlbeck G, et al. (1992) [Intralesional therapy of melanoma metastases with recombinant interferon-beta]. Hautarzt 43(1):16-21.
26. Jackaman C, et al. (2008) Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol 20(11):1467-1479.
27. Green DS, Bodman-Smith MD, Dalgleish AG, Fischer MD (2007) Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. Br J Dermatol 156(2):337-345.
28. Radny P, et al. (2003) Phase II trial of intralesional therapy with interleukin-2 in softtissue melanoma metastases. Br J Cancer 89(9):1620-1626.
29. Chan YP, Meyrueix R, Kravtzoff R, Nicolas F, Lundstrom K (2007) Review on Medusa: A polymer-based sustained release technology for protein and peptide drugs. Expert Opin Drug Deliv 4(4):441-451.
30. Lei C, et al. (2010) Local release of highly loaded antibodies from functionalized nanoporous support for cancer immunotherapy. J Am Chem Soc 132(20):6906-6907.
31. Chai JG, et al. (1999) Critical role of costimulation in the activation of naive antigenspecific TCR transgenic CD8+ T cells in vitro. J Immunol 163(3):1298-1305.
32. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F (2005) Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105(7):2821-2827.
33. Billingham RE, Medawar PB (1951) The technique of free skin grafting in mammals. J Exp Biol 28:385-402.
34. Uyttenhove C, Arendse B, Stroobant V, Brombacher F, Van Snick J (2004) Development of an anti-IL-12 p40 auto-vaccine: Protection in experimental autoimmune encephalomyelitis at the expense of increased sensitivity to infection. Eur J Immunol 34(12):3572-3581.